1. Introduction {#s0005}
===============

Aortic aneurysms and dissections are associated with high morbidity and mortality, accounting for over 152,000 deaths in the United States per annum ([@bb0010]). These are life-threatening diseases due to the predisposition for rupture. About 40% of patients with aortic dissection die immediately and have no enough time to reach a hospital. Aortic medial degeneration (AMD) is considered proceed thoracic aortic aneurysms and dissections (TAAD). AMD is histopathologically characterized by loss of smooth muscle cells (SMCs), and increased proteoglycans degradation.

*SMAD4* plays a pivotal role in the pathological progression of vascular disorder ([@bb0140]). *SMAD4*, a member of Smad family, is a central mediator in the canonical TGF-β signaling. It regulates biological processes important for the pathogenesis of TAAD, such as SMCs migration and proliferation, extracellular matrix degradation ([@bb0090]). *SMAD4*-deficient SMCs can trigger aortic wall inflammation by producing chemokines and recruiting macrophages ([@bb0140]). Besides, *SMAD4* also play essential roles in cardiogenesis, blood vessel remodeling, maturation and integrity ([@bb0050]; [@bb0065]; [@bb0105]; [@bb0130]).

The TGF-β signaling network consists of a complex of ligands, receptors, and transcriptional coregulators that have important effects in vascular remodeling and matrix degradation ([@bb0055]). Mutations of members (*TGFBR1*/*2*, *FBN1*) in this network are causative for disorders hallmarked by aortic aneurysm, e.g. Marfan syndrome (MFS) or Loeys--Dietz syndrome (LDS) ([@bb0080], [@bb0085]). Mutations in a *TGF-β* ligand-*TGF-β2* gene have been recognized as a cause of TAAD with MFS ([@bb0015]). *SMAD4* encodes the only co-smad in TGF-β signaling ([@bb0090]). The mutations of *SMAD4* gene are also important in progression of aortopathy. In Heald\'s retrospective study, the authors described a high prevalence (38%) of aortopathy in patients with juvenile polyposis (JPS) and hereditary hemorrhagic telangiectasia (HHT) is attributed to *SMAD4* mutations ([@bb0035]). Gallione and Andrabi also reported that *SMAD4* mutations could cause a combined JPS & HHT syndrome and vascular disorders (for example, aortic root dilation, multiple arteriovenous malformation) ([@bb0005]; [@bb0025]). Thus, it is interesting to explore the association between variants of *SMAD4* and the pathological progression of TAAD, which may shed light on the role of *SMAD4* in pathogenesis of TAAD and provide a maker for disease diagnosis.

To investigate the genetic effect of *SMAD4* on TAAD, five tagging SNPs were initially genotyped in 202 subjects and 400 healthy controls. The potential function of the significant SNP in the screening dataset was further analyzed by bioinformatic software. A series of experiments was conducted to investigate the potential molecular mechanism of the significant SNP.

2. Materials and Methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

All the experiments involving human specimens were approved by Institutional Review Board (IRB) at the first affiliated hospital of Soochow University from January 2010 to December 2015. In the case-control study, the response rate for cases was 94% (*n* = 223) and for controls 92% (*n* = 437). Each participant has signed the written informed consent. After selecting, 202 patients with TAAD and 400 healthy controls during physical examination were enrolled in the study. All subjects were Han Chinese from eastern China. Patients with familial TAAD were exclude by the following criteria: (1) He/she had one first-degree relative with a documented TAAD history; (2) He/she had two second-degree relatives with TAAD. Controls were frequency matched by age and gender to cases.

The aortic status of subjects were evaluated by at least one type of imaging examination, such as echocardiography, angiography, CT, MRI. Each subject were interviewed in person and filled a structured questionnaire including demographic information, previous medical histories, diet, tobacco and alcohol use, weight, family history of aortopathy. Freshly frozen aortic tissues from 37 TAAD patients were obtained during the Bentall procedures or other large vessels replacement at Department of Cardiovascular Surgery, the first affiliated hospital of Soochow University. Normal aortic tissues were collected from patients who received aortic valve replacement.

2.2. Blood Sample Collection and Genomic DNA Extraction {#s0020}
-------------------------------------------------------

Ethylenediamine tetraacetic acid (EDTA) anticoagulated peripheral blood samples were collected from patients before surgery and healthy controls. Genomic DNA was extracted using a RelaxGene Blood DNA System (TIANGEN biotech, Beijing, China) according to the manufacturer\'s instruction. The laboratory assistant was blinded to the samples about the case-control status.

2.3. SNP Selection and Genotyping {#s0025}
---------------------------------

We selected 5 tagger SNPs by analyzing *SMAD4*-related Han Chinese data from 1000 Genome Project resources (<http://www.1000genomes.org>) using Run Tagger program in Haploview 4.2 (Broad Institute, Cambridge, MA, USA). These SNPs should meet the following criteria: (1) the minor allele frequency (MAF) \> 0.05; (2) r^2^ \> 0.80 for each paired SNPs ([Fig. 1](#f0005){ref-type="fig"}B). rs12455792 (in the 5′UTR, -650C \> T) is located at a transcription factor binding site, with predicted proximal transcriptional regulatory potential (<http://rsnp.psych.ac.cn>/) (<http://snpinfo.niehs.nih.gov/cgi-bin/snpinfo/snpfunc.cgi>). rs61751987, rs12456284, rs3819122 and rs2282544 were also predicted as functional SNPs, which located in the enhancer, chromatin interactive region or other transcriptional regulatory region.Fig. 1Representative MALDI-TOF MS spectra of rs12455792 and linkage disequilibrium (LD) analysis of the tagger SNPs in *SMAD4* gene. (A) Genotypes of rs12455792 are determined by plotting peak intensity (y-axis) against mass (Da) (x-axis). (a) MALDI-TOF MS spectrum of a single peak at 8949.0 Da indicates homozygous genotype of CC. (b) MALDI-TOF MS spectrum of a single peak at 8932.5 Da indicates homozygous genotype of TT. (c) MALDI-TOF MS spectrum of 2 peaks at 8932.5 Da and 8949.0 Da represents heterozygous genotype of CT. (B) Pairwise LD among 5 tagger SNPs of *SMAD4*. The r^2^ value in each diamond indicates the pairwise correlation between SNPs. The color scale ranges from white to black reflects lower to higher r^2^ values.Fig. 1

SNPs were genotyped using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis on the MassARRAY platform (Sequenom, San Diego, CA, USA). The amplification and single-base extension primers applied in multiple PCR were synthesized by Benegene (Benegene Biotechnology, Shanghai, China) and listed in Supplement Table 1. The product of each sample was dispensed onto a 384-format SpectroCHIP with the MassARRAY Nanodispenser RS 1000. Then the MALDI-TOF MS assay was performed on a MassARRAY Compact Analyzer. Genotype calling was conducted in real time with MassARRAY RT software version 3.0. Data was analyzed with MassARRAY Typer software 4.0.3. Genotyping quality was assessed by Sanger sequencing of \~ 15% randomly selected samples, yielding a 100% concordance. The success rates of genotyping for these SNPs were \> 99%.

2.4. Bioinformatic Prediction of Functional SNPs {#s0030}
------------------------------------------------

Since the specific RNA structure determines certain function, we detected the potential change of rs12455792 on RNA folding structure. A 100 bp polymorphism-flanking region RNA was online analyzed using RNAfold (<http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi>) and SNPfold ([http://ribosnitch.bio.unc.edu/Downloads/SNPfold/](http://ribosnitch.bio.unc.edu/Downloads/SNPfold){#ir0025}). SNPs were predicted for putative transcription factor/miRNA binding site applying rSNP (<http://rsnp.psych.ac.cn>/), SNPinfo (<http://snpinfo.niehs.nih.gov/cgi-bin/snpinfo/snpfunc.cgi>) and JASPAR (<http://jaspar.genereg.net>/). The conservation analysis for transcription factor binding sites was performed using Seqlogo (<http://www.bio.cam.ac.uk/seqlogo/logo.cgi>).

2.5. Luciferase Reporter Assay {#s0035}
------------------------------

A 500 bp transcription regulatory sequence (TRS) centered at -650C \> T of *SMAD4* promoter was cloned into the pGL3 basic vector (Promega, Madison, WI, USA). This plasmid was named as pGL3-*SMAD4* TRS reporter ([Fig. 2](#f0010){ref-type="fig"}B(b)). With C allele in the -650C \> T site of TRS, the plasmid was pGL3-*SMAD4* TRS-C allele. Otherwise, the plasmid was pGL3-*SMAD4* TRS-T allele. Day 1, HASMCs and HAECs were seeded at 1 × 10^4^ cells per well in 24-well plates. Day 2, cells were transfected with 800 ng pGL3 basic vector or pGL3-*SMAD4* TRS reporter and 160 ng pRL-TK (Luciferase Assay System; Promega) using Lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad, CA, USA). Day 3, cells were harvested to detect luciferase activity applying the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) on Synergy H1 microplate reader (BioTek Instruments, Winooski, VT, USA). Results were represented as relative luciferase activity to pRL-TK.Fig. 2rs12455792 affected *SMAD4* gene expression. (A) In silico prediction of rs12455792 impact on RNA folding structures. The structures corresponding to rs12455792C (a) or T allele (c). Mountain plots related to rs12455792C (b) or T allele (d). y-axis: minimum free energy or entropy. x-axis: sequence position. (B) Reporter plasmids construction. The schematic diagram of pGL3-basic vector (a) and pGL3-*SMAD4*-TRS reporter (b). (C) Representative graph of relative luciferase activity of cells transfected with pGL-3 basic vector or pGL3-*SMAD4*-TRS reporter. Six replicates for each group and the experiment was repeated at least three times. \**P* \< 0.05. (D) Western blot analysis for *SMAD4* expression in aorta tissues from patients with different genotypes (a) and corresponding quantitative analysis (b).Fig. 2

2.6. Western Blot {#s0040}
-----------------

Protein was extracted from human aorta tissues of 12 TAAD patients or SMCs culture medium, and subjected to western blot with mouse monoclonal antibodies against *SMAD4*, rabbit polyclonal antibodies against Versican or Decorin (1:1000, Abcam, Cambridge, UK). β-actin was used as internal control. The grey scales of target proteins were normalized against β-actin using Gel-Pro analyzer 4.0 (Media Cybernetics, Silver Spring, MD, USA).

2.7. Movat\'s Pentachrome Staining {#s0045}
----------------------------------

Human aortic tissues were fixed in 4% paraformaldehyde, dehydrated in gradient alcohol, transparented in xylene, embedded in paraffin. Histological cross-sections (5 μm) were cut and Movat\'s Pentachrome stained according to the Movat and Schmidt\'s protocols ([@bb0100]; [@bb0125]). In brief, sections were Bouin-fixed and incubated in Hypo solution. Then they were stained using 1% Alcian blue, 10% Weigert hematoxylin, Crocein Scarlet-Acid Fuchsin, phosphotungstic acid, alcoholic Saffron solution step by step.

Quantitative analysis of fibers (brownish-black) and cell counting of SMCs (purple-red) were performed using Image-Pro Plus 6.0 software (Media Cybernetics, Silver Spring, MD, USA). At 200 × magnification, 10 representative staining fields of each section were examined to generate the mean Integrate Optical Density (IOD). IOD represents the intensity of staining signals as detected positive pixels. The data was independently measured by 2 researchers (Y.W. and G.B.). They were blinded to the genetic features of patients. The average IOD difference between two groups (*n* = 5) was statistically analyzed using Student\'s *t-*test.

2.8. Flow Cytometry for Cell Apoptosis {#s0050}
--------------------------------------

After angiotensin II induction for 24 h, cells were digested by 0.25% trypsin (Beyotime, Shanghai, China) and stained by Annexin V-FITC and PI according to the manufacture\'s instruction (Invitrogen Life Technologies, Carlsbad, CA, USA). The fluorescence signals of apoptosis cells were detected on Guava EasyCyte HT Microcapillary flow cytometer (Milipore Corporation, Hayward, CA, USA). The percentages of cells in early-apoptosis or late-apoptosis stage were calculated applying Flowjo software (Tree Star Inc., Ashland, OR, USA).

2.9. Statistical Analysis {#s0055}
-------------------------

Differences of the demographic and clinical characteristics, and frequencies of genotypes in case-control study were tested by the Student\'s *t-*test (for continuous variables) or Chi-square test (for categorical variables). Hardy--Weinberg equilibrium (HWE) was calculated by online analytical tools (<https://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). For the evaluation of main effect of SNPs, univariate and multivariate logistic regression models were conducted to calculate ORs and corresponding 95%CIs with adjustment for possible confounders. All statistical tests were two-sided and performed using Statistical Program for Social Sciences (SPSS 16.0, Chicago, IL, USA) and R (<http://www.r-project.org>/). *P*-value \< 0.05 was considered as statistically significant.

3. Results {#s0060}
==========

3.1. Characteristics of the Study Population {#s0065}
--------------------------------------------

As shown in [Table 1](#t0005){ref-type="table"}, the study included 202 TAAD patients and 400 healthy controls. The cases and controls were adequately frequency-matched for age and sex (*P* = 0.212 and 0.271, respectively). Compared with the cases, the controls were not significantly different in smoking status (*P* = 0.558). Thereafter, these variables were further adjusted for in multivariate logistic regression models.Table 1Demographics and clinical features of the TAAD patients and healthy controls involved in this study.Table 1ItemsCases no. (%)\
*n* = 202Controls no. (%)\
*n* = 400*P* valueAge, years54.1 ± 14.252.4 ± 15.20.212Sex (male), n (%)152 (75.2)284 (71.0)0.271Smoking, n (%)105 (52.0)218 (54.5)0.558Diabetes, n (%)29 (14.4)//Hypertension, n (%)81 (40.1)96 (24.0)**0.000**Body mass index, kg/m^2^23.93 ± 4.0424.32 ± 4.220.124Total cholesterol, mmol/L4.16 ± 1.703.17 ± 1.46**0.033**HDL-c, mmol/L1.15 ± 0.291.28 ± 0.31**0.000**LDL-c, mmol/L2.45 ± 0.802.57 ± 0.970.141[^2]

3.2. Associations of *SMAD4* Genotypes and Hyplotypes With Risk of TAAD {#s0070}
-----------------------------------------------------------------------

The genotype distributions of the five tagger SNPs among the cases and controls were listed in [Table 2](#t0010){ref-type="table"}. Representative graphs of MALDI-TOF MS spectra for rs12455792 were shown in [Fig. 1](#f0005){ref-type="fig"}A. The genotype frequencies in healthy controls were in consistent with the Hardy-Weinberg equilibrium (HWE) (all *P* \> 0.05). Of the 5 SNPs, rs12455792 variant CT/TT genotypes were significantly associated with an increased risk of TAAD. Under the heterozygous model and dominant genetic model, the CT or CT + TT genotypes were significantly associated with higher risk of TAAD (Adjusted OR = 1.51, 1.58; 95%CI = 1.01--2.24, 1.09--2.30, respectively), compared with the wild-type homozygous CC genotype. The T allele of rs12455792 was significantly associated with higher risk of TAAD, compared with the C allele (Adjusted OR = 1.35, 95%CI = 1.07--1.72). However, no significant results were found of other 4 SNPs (rs61751987 G \> A, rs12456284 A \> G, rs3819122 A \> C, rs2282544 G \> C). In haplotype analysis, the frequency of inferred haplotypes of *SMAD4* gene based on observed genotypes and their association with TAAD risk were shown in [Table 3](#t0015){ref-type="table"}. Haplotypes CAACG (*P* = 0.000) and CAGCG (*P* = 0.015) was associated with TAAD risk significantly.Table 2Logistic regression analysis of associations between the genotypes of *SMAD4* and TAAD risk.Table 2VariantsGenotypesCases no. (%)\
*n* = 202Controls no. (%)\
*n* = 400Crude OR (95%CI)*P*[a](#tf0005){ref-type="table-fn"}Adjusted OR (95%CI)*P*[b](#tf0010){ref-type="table-fn"}rs12455792CC52 (25.7)142 (35.5)1.00 (Reference)1.00 (Reference)(HWE = 0.936)CT106 (52.5)192 (48.0)1.51 (1.01--2.24)**0.026**1.51 (1.01--2.24)**0.032**TT44 (21.8)66 (16.5)1.82 (1.11--2.99)**0.013**1.81 (1.11--2.99)**0.016**CT + TT150 (74.3)258 (64.5)1.59 (1.09--2.31)**0.009**1.58 (1.09--2.30)**0.011**C allele210 (52.0)476 (59.5)1.00 (Reference)1.00 (Reference)T allele194 (48.0)324 (40.5)1.36 (1.07--1.73)**0.008**1.35 (1.07--1.72)**0.010**rs61751987GG153 (75.7)299 (74.8)1.00 (Reference)1.00 (Reference)(HWE = 0.098)GA41 (20.3)89 (22.3)0.88 (0.54--1.42)0.6240.85 (0.51--1.39)0.685AA8 (4.0)12 (3.0)1.33 (0.45--3.92)0.7871.31 (0.42--3.81)0.829GA + AA49 (24.3)101 (25.3)0.99 (0.63--1.55)1.0000.97 (0.59--1.52)1.000G allele347 (85.9)687 (85.9)1.00 (Reference)1.00 (Reference)A allele57 (14.1)113 (14.1)0.99 (0.49--2.00)1.0000.97 (0.43--1.91)1.000rs12456284AA93 (46.0)195 (48.8)1.00 (Reference)1.00 (Reference)(HWE = 0.065)AG79 (39.1)157 (39.2)0.98 (0.66--1.47)1.0000.96 (0.65--1.45)1.000GG30 (14.9)48 (12.0)1.19 (0.71--1.98)0.6251.15 (0.69--1.89)0.676AG + GG109 (54.0)205 (51.2)1.12 (0.79--1.57)0.5461.11 (0.78--1.56)0.592A allele265 (65.6)547 (68.4)1.00 (Reference)1.00 (Reference)G allele139 (34.4)253 (31.6)1.10 (0.75--1.49)0.4721.09 (0.74--1.48)0.535rs3819122AA68 (33.7)122 (30.5)1.00 (Reference)1.00 (Reference)(HWE = 0.297)AC101 (50.0)207 (51.8)0.88 (0.60--1.28)0.4970.87 (0.59--1.28)0.560CC33 (16.3)71 (17.7)0.83 (0.50--1.39)0.5220.81 (0.48--1.37)0.583AC + CC134 (66.3)278 (69.5)0.87 (0.60--1.24)0.4580.84 (0.55--1.20)0.517A allele237 (58.7)451 (56.4)1.00 (Reference)1.00 (Reference)C allele167 (41.3)349 (43.6)0.84 (0.56--1.27)0.4620.83 (0.55--1.26)0.507rs2282544GG148 (73.3)282 (70.5)1.00 (Reference)1.00 (Reference)(HWE = 0.086)GC47 (23.2)102 (25.5)0.88 (0.59--1.31)0.5480.86 (0.58--1.30)0.617CC7 (3.5)16 (4.0)0.83 (0.34--2.07)0.8230.77 (0.29--1.94)0.865GC + CC54 (26.7)118 (29.5)0.87 (0.60--1.27)0.5050.86 (0.59--1.26)0.542G allele343 (84.9)666 (83.2)1.00 (Reference)1.00 (Reference)C allele61 (15.1)134 (16.8)0.85 (0.47--1.59)0.6270.82 (0.45--1.58)0.679  Combined effect of risk genotypes00 (0)1 (0.2)1.00 (Reference)1.00 (Reference)13 (1.5)15 (3.7)0.39 (0.11--1.37)0.2020.37 (0.09--1.31)0.217229 (14.3)65 (16.2)0.87 (0.54--1.41)0.6350.84 (0.52--1.38)0.642386 (42.6)169 (42.3)1.01 (0.72--1.42)1.0001.03 (0.73--1.46)0.981467 (33.2)123 (30.8)1.11 (0.77--1.60)0.5771.13 (0.77--1.63)0.569517 (8.4)27 (6.8)1.28 (0.68--2.42)0.5071.26 (0.66--2.41)0.496  Trend0--384 (41.6)150 (37.5)1.00 (Reference)1.00 (Reference)4--5118 (58.4)250 (62.5)1.18 (0.84--1.67)0.3741.19 (0.84--1.69)0.362[^3][^4][^5]Table 3The frequency of inferred haplotypes of *SMAD4* gene based on observed genotypes and their associations with TAAD risk.Table 3Haplotypes[a](#tf0015){ref-type="table-fn"}Cases no. (%)\
*n* = 404Controls no. (%)\
*n* = 800Crude OR (95%CI)*P*Adjusted OR (95%CI)*P*[b](#tf0020){ref-type="table-fn"}CGAAG92 (22.8)168 (21.0)1.00 (Reference)1.00 (Reference)CGACG64 (15.8)118 (14.8)1.08 (0.71--1.66)0.7451.06 (0.67--1.68)0.769CGGAG38 (9.4)96 (12.0)0.71 (0.44--1.15)0.1790.65 (0.37--1.09)0.152CGGCG25 (6.2)39 (4.9)1.18 (0.60--2.33)0.7301.15 (0.53--2.41)0.795CAAAG17 (4.2)52 (6.5)0.58 (0.30--1.11)0.1050.72 (0.28--1.42)0.179CGAAC30 (7.4)51 (6.4)1.23 (0.57--1.96)1.0001.25 (0.61--2.12)1.000CGGAC12 (3.0)18 (2.3)0.73 (0.25--2.16)0.5990.79 (0.21--2.35)0.623CGACC11 (2.7)18 (2.3)1.12 (0.42--2.96)1.0001.23 (0.57--4.21)1.000CAACG6 (1.5)52 (6.5)0.21 (0.09--0.53)**0.000**0.20 (0.08--0.51)**0.000**CAGCG0 (0)6 (0.8)0.49 (0.44--0.54)**0.015**0.45 (0.41--0.52)**0.023**TAAAG39 (9.7)54 (6.8)0.53 (0.90--2.62)0.1380.56 (0.90--2.69)0.159TGACG16 (4.0)26 (3.3)1.29 (0.57--2.89)0.6801.26 (0.54--2.97)0.716TGGCG14 (3.5)24 (3.0)1.17 (0.53--2.59)0.8401.15 (0.47--2.52)0.876TGAAG29 (7.2)44 (5.5)1.36 (0.75--2.45)0.3691.32 (0.69--2.32)0.423TGACC5 (1.2)28 (3.5)0.32 (0.10--0.99)**0.044**0.35 (0.11--1.05)0.076TGGAG6 (1.5)6 (0.8)2.01 (0.50--8.15)0.5031.95 (0.45--7.59)0.582[^6][^7]

3.3. Association of rs12455792 Genotypes and *SMAD4* Expression {#s0075}
---------------------------------------------------------------

rs12455792 is located in the 5′UTR of *SMAD4* gene (-650) and it is predicted to affect the activity of transcription factor binding site (Supplement Fig. 1). While allele C changes to T, both the number of potential binding factors and affinity scores are decreased (Supplement Fig. 2A). Sequence logo graph indicated a high conservation of C allele in Sox6 binding site (Supplement Fig. 2B). In a word, this locus is important in transcriptional regulation. To evaluated the potential impact of rs12455792 on *SMAD4* expression, we constructed two reporter plasmids containing either rs12455792 C or T allele and transfected them into HASMCs or HAECs. As shown in [Fig. 2](#f0010){ref-type="fig"}, the pGL3-*SMAD4* TRS-C allele presented a significantly higher relative luciferase activity, compared with pGL3-*SMAD4* TRS-T allele in HASMCs and HAECs. These data suggested that rs12455792 C → T change in 5′UTR might decrease the transcriptional activity of *SMAD4*. According to RNAfold prediction, local folding structures of rs12455792 flanking-region RNA in the 5′UTR of *SMAD4* greatly changed with the C → T alteration, with the minimum free energy increasing from − 8.30 to − 7.80 kcal/mol ([Fig. 2](#f0010){ref-type="fig"}A). This change might affect RNA protein binding and *SMAD4* expression. We further detected the *SMAD4* expression in freshly frozen aorta tissues from patients with different genotype. The quantitative analysis of western blot indicated that *SMAD4* expression was significant higher in samples with CC genotype than that in samples with variant CT or TT genotype ([Fig. 2](#f0010){ref-type="fig"}D). These findings were in consistent with the data of luciferase reporter assay.

3.4. The Variant rs12455792 Aggravated Versican Degradation via ADAMTS-4 {#s0080}
------------------------------------------------------------------------

Given the observed significant association between rs12455792 and TAAD risk, we further measured the levels of Versican and Decorin degradation products in aortic tissues from patients with CC, CT and TT genotypes. As shown in [Fig. 3](#f0015){ref-type="fig"}, the levels of Versican (fragment of 95 kDa and 70 kDa) and Decorin (fragment of 50 kDa) degradation products were significantly higher in tissues with variant CT or TT than in that with CC genotype. As ADAMTS-1 and ADAMTS-4 levels were strongly correlated with Versican degradation in aortic tissues ([@bb0110]), we hypothesized that *SMAD4* might influence the expression of ADAMTS-1/4. The results of western blot assay suggested that ADAMTS-4 (not ADAMTS-1) expression was significantly higher in *SMAD4*-silenced HASMCs than that in negative control (NC) HASMCs ([Fig. 3](#f0015){ref-type="fig"}C). In cell medium, the Versican degradation was more serious after *SMAD4*-silenced, but rescued by ADAMTS-4 inhibitor ([Fig. 4](#f0020){ref-type="fig"}D). These evidences indicated that *SMAD4* inhibited the ADAMTS-4 effects on Versican degradation.Fig. 3*SMAD4* inhibited Versican and Decorin degradation via ADAMTS-4. Western blot analysis and quantitative analysis for Versican (A) or Decorin (B) degradation products in aortic tissues of patients. \**P* \< 0.05, ns: not significant. (C) Western blot analysis for ADAMTS-1/4 protein levels in *SMAD4*-silenced cells or not. (D) Versican degradation products detection in medium of cells with different treatment.Fig. 3Fig. 4*SMAD4* inhibited the apoptosis of HASMCs. (A) Movat\'s pentachrome staining of normal aortic tissues or tissues from TAAD patients with different genotype. In each group, Scale bar = 50 μm (left)/100 μm (right). (B) Representative scatterplots of flow cytometry for apoptosis analysis. (a) FSC/SSC scatterplot for cells gating. Annexin V-FITC/PI scatterplots of parental (b), siRNA-NC (c), siRNA-SMAD4 (d) group. Quantitative analysis of SMCs (C) and fibers (D) (*n* = 5). \**P* \< 0.05. (E) Percentages of early or late-stage apoptotic cells in different groups.\**P* \< 0.05. All experiments were performed in triplicates. Data was presented as mean ± SD.Fig. 4

3.5. The Variant rs12455792 Promoted the Apoptosis of HASMCs {#s0085}
------------------------------------------------------------

It is known to all that loss of medial SMCs makes an important contribution to aortic aneurysm and dissection because the cell population is capable of directing connective tissue repair. To detect the alteration of SMCs and fibers, we performed Movat\'s pentachrome staining in aortic tissues from different group. Compared to normal aortic tissues, which were full of SMCs (purple-red) ([Fig. 4](#f0020){ref-type="fig"}A), the amount of SMCs was really significantly lower in tissues from TAAD patients. Quantitative analysis revealed that the numbers of SMCs were significantly higher in CC group than that in CT/TT group ([Fig. 4](#f0020){ref-type="fig"}C). However, the IOD of elastic and reticular fibers (brownish-black) in CC group was much lower, compared with that in CT or TT group ([Fig. 4](#f0020){ref-type="fig"}D). As described above, *SMAD4* expression was associated with the variant of rs12455792. Thus we further detected the apoptosis of HASMCs transfected with siRNA-NC or siRNA-*SMAD4* ([Fig. 4](#f0020){ref-type="fig"}B). After induction of angiotensin II for 24 h, both the rate of early and late apoptotic cells (%) in siRNA-*SMAD4* group was notably higher, compared with that in siRNA-NC group. These phenomena suggested that the inhibition of *SMAD4* expression increased angiotensin II-induced apoptosis of SMCs. Wild type C allele of rs12455792 might be a protect factor which prevented SMCs from apoptosis.

4. Discussion {#s0090}
=============

The TGF-β superfamily is composed of various secreted polypeptides which regulate cell proliferation, differentiation and tissue morphogenesis in many organisms ([@bb0135]). *SMAD4* has been recently identified as the unique co-smad which mediates the responses to TGF-β and related factors. Multiple studies in animal models showed that the deficiency of *SMAD4* contributed to the development of thoracic aortic aneurysm or other vascular disorder ([@bb0065]; [@bb0090]; [@bb0140]). In the present study, we investigated the genetic effects of *SMAD4* on the pathogenesis of TAAD. Five tagger SNPs were genotyped in 202 TAAD patients and 400 healthy controls. There was a significant association between individuals carrying at least one T allele of rs12455792 and an increased risk of TAAD. In functional analysis, we found that the variant reduced *SMAD4* expression, thus promote proteoglycans degradation and SMCs apoptosis, which were important pathophysiological processes in TAAD ([Fig. 5](#f0025){ref-type="fig"}).Fig. 5Schematic diagram for potential roles of the SMAD4 variant in pathological progression of TAAD. Variant T allele of rs12455792 might inhibit SMAD4 expression by affecting the affinity between transcription factors and 5′UTR of this gene, resulting in MSCs apoptosis and Versican degradation, and further facilitate the progress of TAAD.Fig. 5

rs12455792 is located in the 5′UTR of *SMAD4*. This locus is predicted as a transcription factors binding site, with proximal transcriptional regulatory potential. While allele C changes to T, both the number of potential binding factors and affinity scores are decreased. Sequence logo graph indicated a high conservation of C allele in Sox6 binding site (Supplemental Fig. 2). These analyses determined the significance of this locus in transcriptional regulation. In view of the evidences shown in [Fig. 1](#f0005){ref-type="fig"}, rs12455792 C → T change reduced the transcriptional activity, altered the RNA folding structure, and decreased *SMAD4* expression. Except for the reduced affinity of transcription factor and -650 region DNA, the C to T substitution also changed RNA folding structure greatly. RNA hairpin structure might act like a hinge that open up DNA and bind the kinase domain. However, the variant of C to T might attenuated the function of RNA hairpin structure, thus down-regulated gene expression. To the best of our knowledge, rs12455792 is a functional SNP involved in the pathogenesis of TAAD. Although it has been reported in cancer metastasis ([@bb0075]), the present study is the first to demonstrate potential function of this SNP.

Another intriguing finding was that rs12455792 might modulate the essential pathophysiological processes in TAAD-SMCs apoptosis, fibers accumulation and proteoglycans degradation, by fine tuning the *SMAD4* expression. As we all known, the aorta is composed of 3 layers: tunica intima, tunica media and tunica adventitia. The tensile strength and elasticity of the aorta mainly depend on the tunica media, which is formed of concentrically arranged elastic fibers and SMCs ([@bb0095]). In response to pulsatile blood flow, SMCs regulate blood flow and pulse pressure via contracting and secreting vascular regulatory factors ([@bb0095]). Loss of vascular SMCs is a key event in progression of TAAD. Our study showed that the numbers of SMCs in tissues from CC group was significantly higher than variant group. The status of SMCs loss was more graveness in the latter. While *SMAD4* expression was lower in variant group as described in [Fig. 2](#f0010){ref-type="fig"}, we hypothesized that SMCs loss might be related to decreased *SMAD4* expression, since it played a pivotal role in SMCs proliferation and blood vessel remodeling. After induction of angiotensin II for 24 h, the percentage of both early and late-stage apoptotic cells were notably higher in siRNA-*SMAD4* group. This suggested that *SMAD4* was really important in maintenance of the SMCs number and normal physiological function of aorta. We also found that the elastic fibers and reticular fibers (brownish-black) were more disorganized and accumulated in tissues from patients with CT or TT genotype. This suggested that rs12455792 might be associated with fiber organization. Although there were no literatures about relationship between fibers accumulation and vascular disorders, we believed that the increase of components in connective tissues might destroy the structural and functional integrity of aortic wall, and reduce its reactive potency to changed blood pressure. *SMAD4* might be involved in this process. These viewpoints needed more investigations to confirm.

We further demonstrated that the proteoglycans (e.g. Versican, Decorin) in matrix degraded more seriously in aorta tissues from CT or TT groups. Proteoglycans interact with hyaluronan to form large aggregates. They can retain water and create reversible compressive layer to protect vascular from lesions of pressure waves and shearing force ([@bb0070]). Thus, proteoglycans may play a pivotal role in maintaining the structural and functional integrity of the vascular wall. The degradation of proteoglycans may be responsible for vascular diseases ([@bb0020]; [@bb0060]). In TAAD tissues, we observed that the degradation of Versican and Decorin was related to rs12455792 genotypes. Moreover, western blot data showed a significantly increased degradation of Versican in *SMAD4*-silenced SMCs, but it was rescued after the addition of ADAMTS-4 inhibitor. Our findings suggested that *SMAD4* low expression might promote Versican degradation via ADAMTS-4. Versican was reported as main proteoglycan substrate of ADAMTS proteinases in the aorta ([@bb0120]). With Movat\'s pentachrome ([Fig. 4](#f0020){ref-type="fig"}), we found that proteoglycans aggregates (aggregates without degradation were stained as bright-blue) were more in CC group than that in CT or TT group. This was consistent with the degradation status of relative groups which were reflected by western blot.

There were several limitations in the current study: (1) Since all the subjects were recruited from eastern Han Chinese population, the association between *SMAD4* SNPs and risk of TAAD might not be generalized to other ethnic groups. (2) Large cohort, multi-center investigations should be performed to provide more potent statistical power. (3) TAAD is a complicated process. Inflammation and lymphocytes recruitment often accompany medial degeneration in the pathogenesis of TAAD ([@bb0030]). Activated T cells and macrophages may contribute to the apoptosis of SMCs and degradation of the matrix ([@bb0030]). Generous studies revealed that low *SMAD4* expression might facilitate lymphocytes accumulation and infiltration ([@bb0040]; [@bb0045]; [@bb0115]; [@bb0140]). Therefore, the association between rs12455792 and inflammation or lymphocytes recruitment in the progression of TAAD is encouraging enough to warrant further investigations.

In summary, we demonstrated that *SMAD4* rs12455792 CT, TT genotypes might increase the risk of TAAD by promoting proteoglycans degradation and SMCs apoptosis. To the best of our knowledge, this is the first study of relationship between functional polymorphisms of *SMAD4* and pathogenic mechanism of TAAD. In a relatively complete investigation, the downstream impacts of SNPs on protein function and pathological progression should be clarified. Therefore the tissues from patients are very pivotal. The thoracic aorta tissues are difficult to obtain, for this reason studies in this area is infrequent. In the current study, SNP rs12455792 is located in the transcription factor binding site and the allele change influences transcription activity and *SMAD4* expression. Decrease of *SMAD4* expression promotes proteoglycans degradation, vascular SMCs apoptosis and fiber accumulation, which are involved in pathological progression of TAAD. rs12455792 might be a potential therapeutic marker in vascular media pathological changes related thoracic aortic disorders.
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